BioSpace News Archive

Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that the company has produced 1.5 mg psilocybin microdose capsules

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (“Defence” or the “Company”), a Canadian biopharmaceuticals company primarily focussed on the development of novel immune-oncology vaccines and drug delivery technologies including Antibody Drug Conjugate (“ADC”), is pleased to announce that a notice of allowance has been issued by the Japan Patent Office for its Japanese patent application no. 2018-568469.

The latest market analysis report published by Reports and Data, titled ‘Global Acute Gout Flare Treatment Market – Forecast to 2030,’ thoroughly examines the Acute Gout Flare Treatment industry to provide essential data & information for the targeted readers.

The latest market analysis report published by Reports and Data, titled ‘Global Adult Onset Growth Hormone Deficiency (GHD) Treatment Market – Forecast to 2030,’ thoroughly examines the Adult Onset Growth Hormone Deficiency (GHD) Treatment industry to provide essential data & information for the targeted readers.

The latest market analysis report published by Reports and Data, titled ‘Global Alpha Thalassemia Market – Forecast to 2030,’ thoroughly examines the Alpha Thalassemia industry to provide essential data & information for the targeted readers.

The latest market analysis report published by Reports and Data, titled ‘Global Bronchial Spasm Treatment Market – Forecast to 2030,’ thoroughly examines the Bronchial Spasm Treatment industry to provide essential data & information for the targeted readers.

A preclinical study presented at the Military Health System Research Symposium this month demonstrated that the proprietary† Absorbable Biocompatible Chitosan investigational product from Tricol Biomedical is both absorbable and biocompatible in an internal bleeding rodent model.

AffyImmune Therapeutics, Inc., a clinical stage biotechnology company using its Tune & Track platform to develop CAR T cells for the treatment of solid cancers, announced today that serial biotech entrepreneur Robert Forrester has been appointed to its Board of Directors.

GE Healthcare announced US FDA 510(k) clearance of its breakthrough AIR Recon DL for 3D and PROPELLER imaging sequences.

InflammX Therapeutics, Inc. (InflammX), a privately held biopharmaceutical company, today announced the submission of an Investigational New Drug (IND) Amendment to U.S. Food and Drug Administration (FDA), to enable the commencement of clinical trials with Xiflam™, an orally administered NLRP3 inflammasome inhibitor with broad application that is formulated as a tablet.